What is Immunai?
Founded in 2018 and headquartered in New York City, Immunai operates at the intersection of computational biology and artificial intelligence. The company provides a sophisticated software platform designed to map and analyze the human immune system with unprecedented granularity. By integrating multi-omics data, Immunai enables researchers and pharmaceutical developers to identify novel drug targets and optimize clinical trial outcomes. Its market position is defined by its ability to transform high-dimensional biological data into actionable insights, effectively bridging the gap between raw immunological research and clinical application.
How much funding has Immunai raised?
Immunai has raised a total of $295M across 3 funding rounds:
Angel/Seed
$20M
Series A
$60M
Series B
$215M
Angel/Seed (2020): $20M with participation from TLV Partners and Viola Group
Series A (2021): $60M, investors not publicly disclosed
Series B (2021): $215M supported by Koch Disruptive Technologies, Talos, 8VC, and Alexandria Venture Investments
Key Investors in Immunai
TLV Partners
An Israeli venture capital firm specializing in early-stage startups, focusing on category-defining companies across AI, healthcare, and application security.
Viola Group
A leading technology investment group managing over $6 billion in assets, providing multi-strategy support to transformational technology companies.
Alexandria Venture Investments
The strategic venture capital arm of Alexandria Real Estate Equities, focusing on innovative life science and healthcare technology companies.
What's next for Immunai?
With the infusion of capital from its latest financing, Immunai is poised to expand its enterprise-level operations and deepen its research capabilities. The strategic focus will likely shift toward scaling its platform to support a broader range of therapeutic areas and enhancing its predictive modeling tools. As the company matures, it is expected to forge deeper partnerships with global pharmaceutical entities, further cementing its role as a foundational technology provider in the precision medicine landscape. The firm's ability to maintain its competitive edge will depend on its continued success in translating complex immune profiles into successful drug development pipelines.
See full Immunai company page
